Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 6/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110060 | 0.82 | AKR1C1 (0.57) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL16060703 | 0.82 | AKR1C3 (0.55) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL16061601 | 0.82 | APP (0.48) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL20195005 | 0.78 | AKR1C3 (0.54) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL20365030 | 0.75 | AKR1C3 (0.48) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL30223686 | 0.75 | LMNA (0.50) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL1465569 | 0.75 | LMNA (0.50) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL16353290 | 0.75 | AKR1C3 (0.78) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL12050450 | 0.74 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL31045572 | 0.74 | APP (0.50) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290357-A | Heterocyclic compounds useful in the treatment of disease | 艾匹根生物技术有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-105142635-B | Heterocyclic compounds useful for the treatment of diseases | 艾匹根生物技术有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3807254-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-2988743-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2988743-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014145873-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | AKR1C3 347/4885AKR1C2 598/4885AKR1C1 757/4885 |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | LPAR1, LPAR4, LPAR2 | AKR1C3 236/4885AKR1C2 436/4885AKR1C1 543/4885 |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | AKR1C3 301/4885AKR1C2 662/4885AKR1C1 725/4885 |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | AKR1C3 301/4885AKR1C2 662/4885AKR1C1 725/4885 |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR4, LPAR3 | AKR1C3 296/4885AKR1C2 662/4885AKR1C1 711/4885 |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR4, LPAR3 | AKR1C3 301/4885AKR1C2 662/4885AKR1C1 725/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | AKR1C3 347/4885AKR1C2 598/4885AKR1C1 757/4885 |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR2, LPAR4 | AKR1C3 623/4885AKR1C2 790/4885AKR1C1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.